摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

[N-[(7-amidino-2-naphthyl)methyl]-N-[4-[(4-piperidyl)oxy]phenyl]sulfamoyl]acetamide | 179755-89-6

中文名称
——
中文别名
——
英文名称
[N-[(7-amidino-2-naphthyl)methyl]-N-[4-[(4-piperidyl)oxy]phenyl]sulfamoyl]acetamide
英文别名
2-[(7-Carbamimidoylnaphthalen-2-yl)methyl-(4-piperidin-4-yloxyphenyl)sulfamoyl]acetamide
[N-[(7-amidino-2-naphthyl)methyl]-N-[4-[(4-piperidyl)oxy]phenyl]sulfamoyl]acetamide化学式
CAS
179755-89-6
化学式
C25H29N5O4S
mdl
——
分子量
495.602
InChiKey
OLMKZCMROYRGJR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.8
  • 重原子数:
    35
  • 可旋转键数:
    9
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.28
  • 拓扑面积:
    160
  • 氢给体数:
    4
  • 氢受体数:
    7

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    [N-[(7-amidino-2-naphthyl)methyl]-N-[4-[(4-piperidyl)oxy]phenyl]sulfamoyl]acetamide 生成 (N-{4-[(1-acetimidoyl-4-piperidyl)oxy]phenyl}-N-[(7-amidino-2-naphthyl)methyl]sulfamoyl)acetamide dihydrochloride
    参考文献:
    名称:
    Amidinonaphthyl derivative or salt thereof
    摘要:
    以下是由下列通式(I)表示的酰胺基萘衍生物,具有凝血因子X抑制作用,可用作抗血栓剂等,其盐,中间体以及包括该酰胺基萘衍生物的药物组成物。由下列通式(I)或其药学上可接受的盐表示的酰胺基萘衍生物。 ##STR1## (式中符号的含义如下:R1:氢原子或由公式--A--W--R4表示的基团,A:由公式表示的基团##STR2##由公式表示的基团##STR3##或由公式--SO.sub.2--表示的基团,X:氧原子或硫原子,W:单键或由公式--NR5--表示的基团,R4:羟基,低级烷氧基等,R5:氢原子,氨基甲酰基,低级烷氧羰基基团等,R2:低级烷基,R3:氢原子,卤原子,羧基,B:低级烷基撑或羰基基团,n:0或1)。
    公开号:
    US05869501A1
  • 作为产物:
    参考文献:
    名称:
    The Discovery of YM-60828: A Potent, Selective and Orally-Bioavailable Factor Xa Inhibitor
    摘要:
    Since Factor Xa (FXa) is well known to play a central role in thrombosis and hemostasis, inhibition of FXa is an attractive target for antithrombotic strategies. As a part of our investigation of a non-peptide, orally available FXa inhibitor, we found that a series of N-[(7-amidino-2-naphthyl)methyl]aniline derivatives possessed potent and selective inhibitory activities. Structure-activity relationship (SAR) of the substituent (R-1) on the central aniline moiety suggested that increasing lipophilicity caused a detrimental effect on anticoagulant activity (prothrombin time assay) in plasma. Several compounds bearing a hydrophilic substituent in R-1 showed not only potent FXa inhibitory activities but also high anticoagulant activities. The best compound in this series was sulfamoylacetic acid derivative 8o (YM-60828) which was a potent, selective and orally bioavailable FXa inhibitor and was chosen for clinical development. (C) 2002 Elsevier Science Ltd. All rights reserved.
    DOI:
    10.1016/s0968-0896(01)00418-7
点击查看最新优质反应信息

文献信息

  • NOVEL AMIDINONAPHTHYL DERIVATIVE OR SALT THEREOF
    申请人:YAMANOUCHI PHARMACEUTICAL CO. LTD.
    公开号:EP0798295A1
    公开(公告)日:1997-10-01
    An amidinonaphthyl derivative represented by the following general formula (I) which has a platelet aggregation inhibiting action based on the activated blood coagulation factor X inhibiting action and is useful as an anti-thrombus agent and the like, a salt thereof, an intermediate thereof and a pharmaceutical composition which comprises the amidinonaphthyl derivative. An amidinonaphthyl derivative represented by the following general formula (I) or a pharmaceutically acceptable salt thereof. (symbols in the formula have the following meanings; R1: a hydrogen atom or a group represented by the formula -A-W-R4, A: a group represented by the formula a group represented by the formula or a group represented by the formula -SO2-, X: an oxygen atom or a sulfur atom, W: a single bond or a group represented by the formula -NR5-, R4: a hydroxyl group, a lower alkoxy group, etc., not a hydroxyl group or a lower alkoxy group, R5: a hydrogen atom, a carbamoyl group, a lower alkoxycarbonyl group, etc., R2: a lower alkyl group, R3: a hydrogen atom, a halogen atom, a carboxyl group, B: a lower alkylene group or a carbonyl group, and n: 0 or 1).
    一种由下式通式(I)表示的脒基萘衍生物、其盐、中间体和包含该脒基萘衍生物的药物组合物,该脒基萘衍生物具有基于活化血液凝固因子 X 抑制作用的血小板聚集抑制作用,可用作抗血栓剂等。 由以下通式(I)代表的脒基萘衍生物或其药学上可接受的盐。 (式中符号含义如下; R1:氢原子或由式-A-W-R4 所代表的基团、 A:由式 式所代表的基团 或由式 -SO2- 代表的基团、 X:氧原子或硫原子,W:单键或由式-NR5-代表的基团,R4:羟基、低级烷氧基等,不是羟基或低级烷氧基,R5:氢原子、氨基甲酰基、低级烷氧基羰基等,R2:低级烷基,R3:氢原子、卤素原子、羧基,B:低级亚烷基或羰基,n:0 或 1)。
  • The Discovery of YM-60828: A Potent, Selective and Orally-Bioavailable Factor Xa Inhibitor
    作者:Fukushi Hirayama、Hiroyuki Koshio、Naoko Katayama、Hiroyuki Kurihara、Yuta Taniuchi、Kazuo Sato、Nami Hisamichi、Yumiko Sakai-Moritani、Tomihisa Kawasaki、Yuzo Matsumoto、Isao Yanagisawa
    DOI:10.1016/s0968-0896(01)00418-7
    日期:2002.5
    Since Factor Xa (FXa) is well known to play a central role in thrombosis and hemostasis, inhibition of FXa is an attractive target for antithrombotic strategies. As a part of our investigation of a non-peptide, orally available FXa inhibitor, we found that a series of N-[(7-amidino-2-naphthyl)methyl]aniline derivatives possessed potent and selective inhibitory activities. Structure-activity relationship (SAR) of the substituent (R-1) on the central aniline moiety suggested that increasing lipophilicity caused a detrimental effect on anticoagulant activity (prothrombin time assay) in plasma. Several compounds bearing a hydrophilic substituent in R-1 showed not only potent FXa inhibitory activities but also high anticoagulant activities. The best compound in this series was sulfamoylacetic acid derivative 8o (YM-60828) which was a potent, selective and orally bioavailable FXa inhibitor and was chosen for clinical development. (C) 2002 Elsevier Science Ltd. All rights reserved.
  • Amidinonaphthyl derivative or salt thereof
    申请人:Yamanouchi Pharmaceutical Co. Ltd
    公开号:US05869501A1
    公开(公告)日:1999-02-09
    An amidinonaphthyl derivative represented by the following general formula (I) which has coagulation factor X inhibiting action and is useful as an anti-thrombus agent and the like, a salt thereof, an intermediate thereof and a pharmaceutical composition which comprises the amidinonaphthyl derivative. An amidinonaphthyl derivative represented by the following general formula (I) or a pharmaceutically acceptable salt thereof. ##STR1## (symbols in the formula have the following meanings; R.sup.1 : a hydrogen atom or a group represented by the formula --A--W--R.sup.4, A: a group represented by the formula ##STR2## a group represented by the formula ##STR3## or a group represented by the formula --SO.sub.2 --, X: an oxygen atom or a sulfur atom, W: a single bond or a group represented by the formula --NR.sup.5 --, R.sup.4 : a hydroxyl group, a lower alkoxy group, etc., R.sup.5 : a hydrogen atom, a carbamoyl group, a lower alkoxycarbonyl group, etc., R.sup.2 : a lower alkyl group, R.sup.3 : a hydrogen atom, a halogen atom, a carboxyl group, B: a lower alkylene group or a carbonyl group, and n: 0 or 1).
    以下是由下列通式(I)表示的酰胺基萘衍生物,具有凝血因子X抑制作用,可用作抗血栓剂等,其盐,中间体以及包括该酰胺基萘衍生物的药物组成物。由下列通式(I)或其药学上可接受的盐表示的酰胺基萘衍生物。 ##STR1## (式中符号的含义如下:R1:氢原子或由公式--A--W--R4表示的基团,A:由公式表示的基团##STR2##由公式表示的基团##STR3##或由公式--SO.sub.2--表示的基团,X:氧原子或硫原子,W:单键或由公式--NR5--表示的基团,R4:羟基,低级烷氧基等,R5:氢原子,氨基甲酰基,低级烷氧羰基基团等,R2:低级烷基,R3:氢原子,卤原子,羧基,B:低级烷基撑或羰基基团,n:0或1)。
查看更多